Trial Profile
Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2020
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Falciparum malaria; Malaria
- Focus Therapeutic Use
- Sponsors PATH
- 11 Sep 2020 Status changed from active, no longer recruiting to completed.
- 03 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 18 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.